56
Participants
Start Date
October 22, 2015
Primary Completion Date
March 26, 2019
Study Completion Date
March 26, 2019
PEGPH20
PEGPH20 will be administered as an intravenous (IV) infusion as per the dose schedule specified in the arm description.
Pembrolizumab
Pembrolizumab will be administered as an IV infusion as per the dose schedule specified in the arm description.
University of Rochester, Rochester
Georgetown University Medical Center, Washington D.C.
Johns Hopkins Kimmel Cancer Center, Baltimore
Virginia Cancer Specialists, PC, Fairfax
Emory University, Atlanta
University of Miami/Sylvester Cancer Center, Miami
Holy Cross Hospitals, Fort Lauderdale
University of Alabama at Birmingham, Birmingham
Ohio State University, Columbus
Cleveland Clinic, Cleveland
Gabrail Cancer Center, Canton
Barbara Ann Karmanos Cancer Center, Detroit
University of Chicago, Chicago
Washington University School of Medicine, St Louis
Ochsner Clinic Foundation, New Orleans
Mary Crowley Cancer Research Center, Dallas
University of Colorado Denver University of Colorado Anschutz Medical Campus, Aurora
Innovative Clinical Research, Whittier
California Cancer Associates for Research and Excellence - Encinitas, Encinitas
University of California San Diego - Moores Cancer Center, La Jolla
St. Joseph's Hospital, Orange
St. Joseph's Hospital, Santa Rosa
University of California - Davis, Sacramento
Oregon Health and Science University, Portland
Swedish Health Services, Seattle
Mayo Clinic, Scottsdale, Arizona, Scottsdale
Cleveland Clinic Florida, Weston
New Jersey Hematology Oncology Associates, Brick
Lead Sponsor
Halozyme Therapeutics
INDUSTRY